Double
blind efficacy trials
High responder rates
- 3 double-blind placebo-controlled studies, 904 patients (14 –
70y)
- Levetiracetam dose 1000 - 3000 mg/day
- 8 - 12 weeks baseline, 12 - 14 weeks evaluation
- Maximum 2 concomitant AEDs
- partial seizures with or without secondary generalisation
- treatment resistant epilepsy
- at least 12 seizures / 12 weeks
- at least 2 complex partial seizures/ 4 weeks
- at least 12 seizures / 12 weeks
Pooled data - Dose-response relationship
Pooled data - Efficacy in all partial seizure subtypes
Shorvon et al., Epilepsia 2000;41(9):1179-1186/
Boon et al., Epilepsy Research 2002;48:77-89/
Cereghino et al., Neurology 2000;55:236-242/
Ben-Menachem et al., Epilepsia 2000;41(10):1276-128
Efficacy
and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with
refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled
study
Tsai JJ et al., Epilepsia. 2006 Jan;47(1):72-81.
